Fictional brand for demonstration only. Orevana, kelvesonide and Kestrova Therapeutics were created by Solstice. This is not a real medicine or medical information.
Orevana (kelvesonide) inhalation powder For US healthcare professionals
For healthcare professionals

Start the steady part of asthma care.

Once-daily Orevana (kelvesonide) inhalation powder is an inhaled corticosteroid for the maintenance treatment of asthma in patients 12 years and older.

Orevana inhaler with a lilac cap next to its carton

Indication: Orevana (kelvesonide) inhalation powder is indicated for the long-term, once-daily maintenance treatment of asthma in patients 12 years of age and older. Orevana is not indicated for the relief of acute bronchospasm and is not a rescue inhaler.

See Important Safety Information
Efficacy

Steady control, built day by day.

In KELVA-1, a 52-week, randomized, double-blind, placebo-controlled trial in 1,184 patients aged 12 and older with mild to moderate asthma.1

41%

fewer severe asthma exacerbations vs placebo over 52 weeks (primary endpoint).1

136 mL

improvement in trough FEV1 from baseline vs placebo at week 12.1

1×

One inhalation, once daily, at the same time each day.2

All data shown are fictional and for demonstration purposes only.

Front view of the Orevana inhaler showing the 100 mcg label
Dosing

One inhalation, once a day.

Orevana 100 mcg: one inhalation once daily, at the same time each day.2

  1. OpenRemove the lilac cap until it clicks.
  2. InhaleBreathe out away from the mouthpiece, then inhale steadily and deeply.
  3. Close and rinseReplace the cap, then rinse the mouth with water without swallowing.

Remind patients that Orevana is not a rescue inhaler. They should keep their rescue inhaler with them.

Patient support

Help patients make it part of their morning.

The Orevana Steady Start program helps patients build a daily routine and stay on track.

  • Savings card for eligible commercially insured patients. [Program terms.]
  • Daily reminders and refill alerts by text or email.
  • Step-by-step device videos and printable instructions.
A woman in a lavender sweater holding a mug by a bright kitchen window
Patient portrayal.
Resources

Everything you need to prescribe Orevana.

Prescribing Information

Full PI, including Patient Information.

Download PDF

Dosing guide

One-page dosing and device overview.

View guide

Device video

Show patients how to use the inhaler.

Watch video

Savings program

Enroll eligible patients in Steady Start.

Learn more

Indication

Orevana (kelvesonide) inhalation powder is a prescription inhaled corticosteroid medicine used for the long-term, once-daily maintenance treatment of asthma in people 12 years of age and older. Orevana is not used to relieve sudden breathing problems and is not a rescue inhaler.

Important Safety Information

Do not use Orevana to treat sudden, severe symptoms of asthma. Always have a rescue inhaler with you. Do not use Orevana if you are allergic to kelvesonide or any of its ingredients.

Orevana can cause serious side effects, including:

  • Fungal infection in the mouth or throat (thrush). Rinse your mouth with water without swallowing after each use.
  • Weakened immune system and a higher chance of infections.
  • Reduced adrenal function, especially when switching from oral corticosteroids.
  • Decreased bone mineral density and slowed growth in children and adolescents.
  • Eye problems, including glaucoma and cataracts.
  • Sudden breathing problems right after use. If this happens, stop using Orevana and use your rescue inhaler.
  • Serious allergic reactions. Get emergency help if you have a rash, hives, swelling of the face, mouth or tongue, or trouble breathing.

The most common side effects include upper respiratory tract infection, headache, sore throat and thrush.

Tell your healthcare provider about all the medicines you take and all of your medical conditions.

Please see full Prescribing Information, including Patient Information.

This safety information is a fictional sample created for demonstration purposes.

References
  1. KELVA-1 Clinical Study Report. Kestrova Therapeutics; 2026. Fictional.
  2. Orevana Prescribing Information. Kestrova Therapeutics. Fictional.